These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 24947099)

  • 41. Molecular phenotyping of thyroid tumors identifies a marker panel for differentiated thyroid cancer diagnosis.
    Wiseman SM; Melck A; Masoudi H; Ghaidi F; Goldstein L; Gown A; Jones SJ; Griffith OL
    Ann Surg Oncol; 2008 Oct; 15(10):2811-26. PubMed ID: 18612701
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Usefulness of galectin-3 immunohistochemistry in differential diagnosis between thyroid follicular carcinoma and follicular adenoma.
    Jakubiak-Wielganowicz M; Kubiak R; Sygut J; Pomorski L; Kordek R
    Pol J Pathol; 2003; 54(2):111-5. PubMed ID: 14575419
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Utility of immunohistochemical markers in diagnosis of follicular cell derived thyroid lesions.
    Alshenawy HA
    Pathol Oncol Res; 2014 Oct; 20(4):819-28. PubMed ID: 24659044
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Peroxisome proliferator-activated receptor gamma expression in follicular-patterned thyroid lesions. Caveats for the use of immunohistochemical studies.
    Gustafson KS; LiVolsi VA; Furth EE; Pasha TL; Putt ME; Baloch ZW
    Am J Clin Pathol; 2003 Aug; 120(2):175-81. PubMed ID: 12931546
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Expression of p27kip1 and Ki-67 in benign and malignant thyroid tumors.
    Erickson LA; Jin L; Wollan PC; Thompson GB; van Heerden J; Lloyd RV
    Mod Pathol; 1998 Feb; 11(2):169-74. PubMed ID: 9504687
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Encapsulated papillary oncocytic neoplasms of the thyroid: morphologic, immunohistochemical, and molecular analysis of 18 cases.
    Woodford RL; Nikiforov YE; Hunt JL; Bellizzi AM; Zhang X; Mills SE; Stelow EB
    Am J Surg Pathol; 2010 Nov; 34(11):1582-90. PubMed ID: 20924280
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy.
    de Matos PS; Ferreira AP; de Oliveira Facuri F; Assumpção LV; Metze K; Ward LS
    Histopathology; 2005 Oct; 47(4):391-401. PubMed ID: 16178894
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The prediction of malignant risk in the category "atypia of undetermined significance/follicular lesion of undetermined significance" of the Bethesda System for Reporting Thyroid Cytopathology using subcategorization and BRAF mutation results.
    Hyeon J; Ahn S; Shin JH; Oh YL
    Cancer Cytopathol; 2014 May; 122(5):368-76. PubMed ID: 24591408
    [TBL] [Abstract][Full Text] [Related]  

  • 49. HBME1 and CK19 expression in non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) vs other follicular patterned thyroid lesions.
    Sadiq Q; Sekhri R; Dibaba DT; Zhao Q; Agarwal S
    World J Surg Oncol; 2021 May; 19(1):143. PubMed ID: 33964951
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prohibitin is overexpressed in papillary thyroid carcinomas bearing the BRAF(V600E) mutation.
    Franzoni A; Dima M; D'Agostino M; Puppin C; Fabbro D; Loreto CD; Pandolfi M; Puxeddu E; Moretti S; Celano M; Bruno R; Filetti S; Russo D; Damante G
    Thyroid; 2009 Mar; 19(3):247-55. PubMed ID: 19207009
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A high-throughput proteomic approach provides distinct signatures for thyroid cancer behavior.
    Cheng S; Serra S; Mercado M; Ezzat S; Asa SL
    Clin Cancer Res; 2011 Apr; 17(8):2385-94. PubMed ID: 21389096
    [TBL] [Abstract][Full Text] [Related]  

  • 52. BRAF (V600E) mutation analysis on liquid-based cytology-processed aspiration biopsies predicts bilaterality and lymph node involvement in papillary thyroid microcarcinoma.
    Rossi ED; Martini M; Capodimonti S; Lombardi CP; Pontecorvi A; Vellone VG; Zannoni GF; Larocca LM; Fadda G
    Cancer Cytopathol; 2013 Jun; 121(6):291-7. PubMed ID: 23192956
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Familial non-medullary thyroid carcinoma (FNMTC): analysis of fPTC/PRN, NMTC1, MNG1 and TCO susceptibility loci and identification of somatic BRAF and RAS mutations.
    Cavaco BM; Batista PF; Martins C; Banito A; do Rosário F; Limbert E; Sobrinho LG; Leite V
    Endocr Relat Cancer; 2008 Mar; 15(1):207-15. PubMed ID: 18310288
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Diagnostic value of BRAFV600E and RET/PTC oncogenes in thyroid nodule aspirates].
    Guerra A; Carrano M; Angrisani E; Vitale M
    Recenti Prog Med; 2013; 104(7-8):415-9. PubMed ID: 24042420
    [TBL] [Abstract][Full Text] [Related]  

  • 55. HBME-1 immunostaining in thyroid tumors especially in follicular neoplasm.
    Mase T; Funahashi H; Koshikawa T; Imai T; Nara Y; Tanaka Y; Nakao A
    Endocr J; 2003 Apr; 50(2):173-7. PubMed ID: 12803237
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-{gamma}, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma.
    Liu YY; Morreau H; Kievit J; Romijn JA; Carrasco N; Smit JW
    Eur J Endocrinol; 2008 Mar; 158(3):375-84. PubMed ID: 18299472
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Primary pure squamous cell carcinoma of the thyroid: report and histogenic consideration of a case involving a BRAF mutation.
    Ko YS; Hwang TS; Han HS; Lim SD; Kim WS; Oh SY
    Pathol Int; 2012 Jan; 62(1):43-8. PubMed ID: 22192803
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Diagnostic and prognostic value of angiogenesis-modulating genes in malignant thyroid neoplasms.
    Kebebew E; Peng M; Reiff E; Duh QY; Clark OH; McMillan A
    Surgery; 2005 Dec; 138(6):1102-9; discussion 1109-10. PubMed ID: 16360397
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Correlation between BRAF mutation and the clinicopathological parameters in papillary thyroid carcinoma with particular reference to follicular variant.
    Smith RA; Salajegheh A; Weinstein S; Nassiri M; Lam AK
    Hum Pathol; 2011 Apr; 42(4):500-6. PubMed ID: 21167555
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunohistochemical analysis of nm23 protein expression in thyroid papillary carcinoma and follicular neoplasm.
    Tabriz HM; Adabi Kh; Lashkari A; Heshmat R; Haghpanah V; Larijani B; Tavangar SM
    Pathol Res Pract; 2009; 205(2):83-7. PubMed ID: 18996649
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.